141 related articles for article (PubMed ID: 10798814)
1. Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Solc Z; Huff W; Cantor A; Steele J; Webster C; Donohue M
Tech Urol; 2000 Jun; 6(2):128-34. PubMed ID: 10798814
[TBL] [Abstract][Full Text] [Related]
2. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
3. Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Steele J; Webster C; Donohue M; Solc Z; Huff W; Cantor A
J Endourol; 2000 May; 14(4):343-50. PubMed ID: 10910150
[TBL] [Abstract][Full Text] [Related]
4. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
5. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Solc Z; Huff W; Cantor A
Urology; 1998 May; 51(5):796-803. PubMed ID: 9610594
[TBL] [Abstract][Full Text] [Related]
6. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
Stock RG; Berkowitz J; Blacksburg SR; Stone NN
BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680
[TBL] [Abstract][Full Text] [Related]
7. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer.
Prestidge BR; Hoak DC; Grimm PD; Ragde H; Cavanagh W; Blasko JC
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):31-9. PubMed ID: 9054874
[TBL] [Abstract][Full Text] [Related]
8. Biopsy results after real-time ultrasound-guided transperineal implants for stage T1-T2 prostate cancer.
Stone NN; Stock RG; Unger P; Kao J
J Endourol; 2000 May; 14(4):375-80. PubMed ID: 10910155
[TBL] [Abstract][Full Text] [Related]
9. Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation.
Stone NN; Stock RG
Tech Urol; 1995; 1(2):72-80. PubMed ID: 9118374
[TBL] [Abstract][Full Text] [Related]
10. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
11. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
12. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate.
Stone NN; Ramin SA; Wesson MF; Stock R; Unger P; Klein G
J Urol; 1995 May; 153(5):1555-60. PubMed ID: 7536266
[TBL] [Abstract][Full Text] [Related]
13. Predictors of metastatic disease after prostate brachytherapy.
Forsythe K; Burri R; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025
[TBL] [Abstract][Full Text] [Related]
14. Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present.
Schellhammer PF; Moriarty R; Bostwick D; Kuban D
Urology; 2000 Sep; 56(3):436-9. PubMed ID: 10962309
[TBL] [Abstract][Full Text] [Related]
15. There is a wide range of predictive dosimetric factors for I-125 and pd-103 prostate brachytherapy.
Herstein A; Wallner K; Merrick G; Orio P; Thornton K; Butler W; Sutlief S
Am J Clin Oncol; 2008 Feb; 31(1):6-10. PubMed ID: 18376221
[TBL] [Abstract][Full Text] [Related]
16. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
17. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
18. The use of transrectal ultrasound placement of radioactive seeds for the definitive treatment of prostate cancer.
Zachow SE; Hargis R
J Miss State Med Assoc; 1996 Oct; 37(10):771-5. PubMed ID: 8908949
[TBL] [Abstract][Full Text] [Related]
19. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.
Sharkey J; Cantor A; Solc Z; Huff W; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R
Brachytherapy; 2005; 4(1):34-44. PubMed ID: 15737905
[TBL] [Abstract][Full Text] [Related]
20. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
